rs1051266
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP4_StrongBP6_StrongBA1
The NM_194255.4(SLC19A1):c.80A>G(p.His27Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.556 in 1,600,100 control chromosomes in the GnomAD database, including 249,464 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as drug response (★★★).
Frequency
Consequence
NM_194255.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC19A1 | NM_194255.4 | c.80A>G | p.His27Arg | missense_variant | 2/6 | ENST00000311124.9 | NP_919231.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC19A1 | ENST00000311124.9 | c.80A>G | p.His27Arg | missense_variant | 2/6 | 1 | NM_194255.4 | ENSP00000308895.4 |
Frequencies
GnomAD3 genomes AF: 0.518 AC: 78652AN: 151888Hom.: 20924 Cov.: 32
GnomAD3 exomes AF: 0.550 AC: 125992AN: 228958Hom.: 34859 AF XY: 0.556 AC XY: 69279AN XY: 124500
GnomAD4 exome AF: 0.560 AC: 811122AN: 1448094Hom.: 228513 Cov.: 46 AF XY: 0.562 AC XY: 404045AN XY: 719546
GnomAD4 genome AF: 0.518 AC: 78718AN: 152006Hom.: 20951 Cov.: 32 AF XY: 0.519 AC XY: 38536AN XY: 74280
ClinVar
Submissions by phenotype
Lung cancer Pathogenic:1
Likely pathogenic, no assertion criteria provided | case-control | Scientific Research Center, Shenzhen Evergreen Medical Institute | - | - - |
Gastrointestinal stromal tumor Uncertain:1
Uncertain significance, no assertion criteria provided | case-control | Department of Pharmacy and Biotechnology, University of Bologna | - | - - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
methotrexate response - Efficacy Other:1
drug response, reviewed by expert panel | curation | PharmGKB | Mar 24, 2021 | PharmGKB Level of Evidence 2A: Variants in Level 2A clinical annotations are found in PharmGKB’s Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2A clinical annotations must be supported by at least two independent publications. Drug-variant association: Efficacy |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at